Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

about

A critical review on ramucirumab in the treatment of advanced urothelial cancer.Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.

P2860

Q47787312-832B8C2E-AEC7-43F1-9D0B-EBB11B5B99B3 Q55331865-D311128D-59C6-4746-ACD5-6135F40FB8CD

P2860

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

Item

http://www.wikidata.org/entity/Q38612237

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

@en

type

Item

label

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

@en

prefLabel

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

@en

P1476

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

@en

P2093

Ling Gao

http://www.w3.org/2001/XMLSchema#string

Lisa O'Brien

http://www.w3.org/2001/XMLSchema#string

Paul Westwood

http://www.w3.org/2001/XMLSchema#string

P2860

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

The VEGF family in cancer and antibody-based strategies for their inhibition.

P304

2741-2751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1111/BCP.13403

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Heathman

P577

2017-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28833321

http://www.w3.org/2001/XMLSchema#string

P932

5698573

http://www.w3.org/2001/XMLSchema#string

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

about

P2860

P2860

Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932